Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.
Hidradenitis suppurativa (HS) is a chronic and debilitating skin disorder. Secukinumab, a biologic agent targeting interleukin-17, is a new therapeutic option for HS. However, data regarding its long-term outcomes are scarce.
To evaluate the long-term effectiveness, safety, and predictors of response to secukinumab in a real-world cohort of patients with moderate-to-severe HS.
Multicentre retrospective cohort study across 12 Italian tertiary referral hospitals. The primary effectiveness outcomes were the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) and a 55% reduction in the International Hidradenitis Suppurativa Severity Score System (IHS4-55) at any time point.
A total of 77 patients (53% female; median age 38 years, interquartile range: 27-50) met the inclusion criteria. At week 52, 36.2% of patients achieved HiSCR and 55.6% achieved IHS4-55. The mean reduction from baseline to week 52 was 50.8% for skin pain Numeric Rating Scale and 55.2% for Dermatology Life Quality Index. Agreement between IHS4-55 and HiSCR was 76.6% (Cohen's kappa 0.5255; 95% CI: 0.4307-0.6202, P < .0001). Patients in Hurley stage 3 had a significantly lower hazard ratio (HR) of achieving IHS4-55 than those in Hurley stage 2 (HR 0.52; 95% CI: 0.31-0.89, P = .017), which persisted in the multivariable model (HR 0.56; 95% CI: 0.31-0.99, P = .044). No new safety concerns were identified.
This study suggests that secukinumab provides clinically meaningful long-term outcomes in HS management, even in bio-experienced patients.
To evaluate the long-term effectiveness, safety, and predictors of response to secukinumab in a real-world cohort of patients with moderate-to-severe HS.
Multicentre retrospective cohort study across 12 Italian tertiary referral hospitals. The primary effectiveness outcomes were the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) and a 55% reduction in the International Hidradenitis Suppurativa Severity Score System (IHS4-55) at any time point.
A total of 77 patients (53% female; median age 38 years, interquartile range: 27-50) met the inclusion criteria. At week 52, 36.2% of patients achieved HiSCR and 55.6% achieved IHS4-55. The mean reduction from baseline to week 52 was 50.8% for skin pain Numeric Rating Scale and 55.2% for Dermatology Life Quality Index. Agreement between IHS4-55 and HiSCR was 76.6% (Cohen's kappa 0.5255; 95% CI: 0.4307-0.6202, P < .0001). Patients in Hurley stage 3 had a significantly lower hazard ratio (HR) of achieving IHS4-55 than those in Hurley stage 2 (HR 0.52; 95% CI: 0.31-0.89, P = .017), which persisted in the multivariable model (HR 0.56; 95% CI: 0.31-0.99, P = .044). No new safety concerns were identified.
This study suggests that secukinumab provides clinically meaningful long-term outcomes in HS management, even in bio-experienced patients.
Authors
Avallone Avallone, Roccuzzo Roccuzzo, Valtellini Valtellini, Moltrasio Moltrasio, Genovese Genovese, Repetto Repetto, Aouadi Aouadi, Moglia Moglia, Manzo Margiotta Manzo Margiotta, Schettini Schettini, Martora Martora, Gargiulo Gargiulo, Valenti Valenti, Malvaso Malvaso, Bernardini Bernardini, Dattola Dattola, Conforti Conforti, Marasca Marasca, Derlino Derlino, Maronese Maronese, Giordano Giordano, Satolli Satolli, Dini Dini, Bettoli Bettoli, Megna Megna, Costanzo Costanzo, Peris Peris, Skroza Skroza, Richetta Richetta, Fania Fania, Quaglino Quaglino, Pellacani Pellacani, Marzano Marzano, Ribero Ribero
View on Pubmed